Cdc

• On March 18, 2026, the CDC released a notice finding insufficient evidence to add Anti-Glomerular Basement Membrane (Anti-GBM) Glomerulonephritis to the List of WTC-Related Health Conditions after receiving a petition from the WTC Health Program Administrator. • The decision highlights ongoing evaluations of conditions potentially linked to 9/11 exposures for covered responders and survivors. • This ruling impacts thousands of WTC Health Program participants seeking coverage for emerging renal diseases.

• Respiratory syncytial virus (RSV) hospitalizations declined 42% in the week ending March 20, 2026, compared to the peak surge in February, according to CDC surveillance data. • The decline follows the introduction of the first RSV vaccines approved for adults over 60 and high-risk populations, with over 8 million doses administered since January. • RSV typically causes severe disease in infants and older adults; the new vaccines represent a major breakthrough after decades of failed vaccine development efforts.

• A federal judge on Monday blocked HHS from implementing vaccine policy changes made by RFK Jr.'s revamped CDC Advisory Committee on Immunization Practices (ACIP), reversing all recent decisions. • The ruling leaves unresolved the status of the RSV vaccine for infants, potentially making it no longer free for children who need it, as its inclusion was authorized by the current advisers. • Public health experts are scrambling to understand ramifications, with health groups concerned about unintended harms and weakened vaccination recommendations for hepatitis B and COVID-19.

CDC interim analysis from September 2025 to February 2026 shows this season's flu vaccine effectiveness at 22-34% against outpatient visits for adults and 30-41% for those 65+, with hospitalization protection at 30-31%, due to H3N2 strain mismatch. The season saw 27 million illnesses, 350,000 hospitalizations, and 22,000 deaths, lower than last year's peaks but with 101 child deaths, 85% unvaccinated. Despite flaws, experts like Dr. William Schaffner stress shots prevent severe outcomes, with adult rates at 46.5%. Vaccination campaigns will target improved strains for next season.

CDC studies from September 2025 to February 2026 estimate flu vaccine effectiveness (VE) at 22-34% against influenza A/B outpatient visits for adults and 30-41% for those 65+, with 30-31% against hospitalizations. Patrick Maloney, PhD, from CDC's National Center for Immunization and Respiratory Diseases, led the analysis. Low VE underscores need for improved formulations amid slumping protection. Findings inform next season's vaccine development.

A University of Pennsylvania Annenberg survey reveals only 11% of Americans would follow CDC over American Academy of Pediatrics on vaccine recommendations, signaling severe public health alarm fatigue. RFK Jr.'s leadership gutted the childhood immunization schedule from 17 to 11 vaccines, terminated $500 million in mRNA research contracts, and oversaw 2,200 measles cases with three deaths in 2025, risking loss of elimination status achieved in 2000. CDC trust plummeted from 75% to 60% in one year due to political leadership, though two-thirds still trust career scientists. Protocols are shifting as 77% prefer AAP guidance on vaccinations.